Want to see DWTX full AI Analyst Report?
DWTX Stock Chart & Stats
$1.50
$0.03(2.00%)
At close: 4:00 PM EDT
$1.50
$0.03(2.00%)
Day’s Range― - ―
52-Week Range$1.28 - $9.50
Previous Close$1.53
Volume4.55K
Average Volume (3M)1.54M
Market Cap
$52.13M
Enterprise Value$57.70
Total Cash (Recent Filing)$13.23M
Total Debt (Recent Filing)$144.93K
Price to Earnings (P/E)―
Beta1.95
Next Earnings
Aug 19, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.60
Shares Outstanding33,629,555
10 Day Avg. Volume77,367
30 Day Avg. Volume1,536,657
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.46
Price to Sales (P/S)0.00
P/FCF Ratio-2.19
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$13.50Price Target Upside800.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.59
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetVery low leverage and sizable equity provide durable solvency support for a pre‑commercial biotech. This balance sheet buffer extends runway versus peers, permits continued clinical investment without immediate distress, and improves ability to negotiate financing or partnerships long term.
Authorized-share Increase (financing Flexibility)Board‑approved increase in authorized shares materially enhances strategic flexibility to raise capital via equity, issue preferred stock, or enable transactions. That structural option lowers the risk of being unable to fund clinical programs and supports long‑term program continuity.
Focused Clinical-stage R&DConcentrated scientific focus on pain and neurological indications creates a clear strategic identity and builds domain expertise. If clinical candidates progress, targeted programs can attract partnerships and long‑term commercial opportunities in large, structurally resilient markets.
Bears Say
Pre-revenue ProfileNo commercial revenue means the business model depends entirely on external financing until approval and launch. This structural lack of operating cash inflow raises funding and execution risk, constrains reinvestment options, and places clinical progress as the primary value driver.
Widening Net LossesSharp year‑over‑year loss expansion reflects rising R&D and operating costs, accelerating cash burn. Persistent and increasing losses shorten runway, heighten near‑term financing needs, and raise the risk that resources are diverted from programs or that financing occurs on dilutive or restrictive terms.
Negative Cash Flow And Deteriorating FCFConsistent negative operating cash flow and a steep fall in free cash flow indicate weakening cash generation. This structural cash quality issue increases dependence on capital markets, may force timing changes in development programs, and elevates execution risk over the medium term.
Dogwood Therapeutics News
DWTX FAQ
What was Dogwood Therapeutics’s price range in the past 12 months?
Dogwood Therapeutics lowest stock price was $1.28 and its highest was $9.50 in the past 12 months.
What is Dogwood Therapeutics’s market cap?
Dogwood Therapeutics’s market cap is $52.13M.
When is Dogwood Therapeutics’s upcoming earnings report date?
Dogwood Therapeutics’s upcoming earnings report date is Aug 19, 2026 which is in 19 days.
How were Dogwood Therapeutics’s earnings last quarter?
Dogwood Therapeutics released its earnings results on May 14, 2026. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.193 by $0.043.
Is Dogwood Therapeutics overvalued?
According to Wall Street analysts Dogwood Therapeutics’s price is currently Undervalued.
Does Dogwood Therapeutics pay dividends?
Dogwood Therapeutics does not currently pay dividends.
What is Dogwood Therapeutics’s EPS estimate?
Dogwood Therapeutics’s EPS estimate is -0.14.
How many shares outstanding does Dogwood Therapeutics have?
Dogwood Therapeutics has 33,629,555 shares outstanding.
What happened to Dogwood Therapeutics’s price movement after its last earnings report?
Dogwood Therapeutics reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.193. Following the earnings report the stock price went up 6.452%.
Which hedge fund is a major shareholder of Dogwood Therapeutics?
Currently, no hedge funds are holding shares in DWTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dogwood Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
60.36%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.83%
Trailing 12-Months
Company Description
Dogwood Therapeutics
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.
DWTX Stock 12 Month Forecast
Average Price Target
$13.50
▲(800.00% Upside)
Technical Analysis
Marker Therapeutics
―
BioRestorative Therapies
―
―
Bolt Biotherapeutics
―
Acurx Pharmaceuticals
―
Ownership Overview
73.57% Insiders
0.44% Mutual Funds
<0.01% Other Institutional Investors
25.51% Public Companies and
Individual Investors